--- title: "16:06 ET\n\t\t\t\n\t\t\t\n\t\t\t\tDisrupting Biotech: Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable" description: "Jurek Kozyra, CEO of Nanovery, discusses on the Disruption Interruption podcast how DNA nanorobots and AI are revolutionizing molecular medicine. These innovations aim to reduce drug development times" type: "news" locale: "en" url: "https://longbridge.com/en/news/272746120.md" published_at: "2026-01-15T21:07:04.000Z" --- # 16:06 ET Disrupting Biotech: Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable > Jurek Kozyra, CEO of Nanovery, discusses on the Disruption Interruption podcast how DNA nanorobots and AI are revolutionizing molecular medicine. These innovations aim to reduce drug development times from 10-15 years to mere hours, potentially curing diseases by targeting mRNA. Kozyra highlights the inefficiencies of traditional medicine and the promise of nanorobots that can detect diseases in blood samples within 2-4 hours, significantly faster than conventional methods. This technology has shown promising results in clinical settings, marking a significant advancement in rapid diagnostics and drug discovery. *Jurek Kozyra, CEO of Nanovery, joins host Karla Jo Helms on the Disruption Interruption podcast to discuss revolutionizing molecular medicine. Kozyra reveals how DNA nanorobots and AI are reducing diagnostic wait times from days to hours and accelerating drug development, potentially shortening the decade-long journey to market life-saving treatments.* , /PRNewswire/ -- Bringing a new drug from discovery to market is a grueling marathon that typically requires 10–15 years of research, testing, and regulatory approval. According to recent data, clinical development times for innovative drugs have remained stagnant over the last decade, with a median duration of around 8 years. Jurek Kozyra, founder and CEO of Nanovery, sits down with host Karla Jo Helms on the latest episode of the *Disruption Interruption podcast* to explain how he is dismantling these barriers. Kozyra discusses how the convergence of DNA nanotechnology and AI is creating a new era of "oligo therapeutics" capable of targeting the underlying mechanisms of disease. Continue Reading "If you can target mRNA very specifically, that means that in theory, you could potentially cure all diseases," says Kozyra. "That's why this area is so exciting right now." **The Stagnation of Traditional Medicine** For centuries, medicine has operated on a "lock and key" model, hunting for molecules that can fix defective proteins. However, this approach leaves many diseases untreated simply because scientists cannot find the right molecule to fit the target. Furthermore, the diagnostic process remains dangerously slow; traditional lab tests can take up to two days to return results—a delay that can be fatal in emergency situations like drug overdoses. Pharmaceutical companies are also racing against the clock. "Pharma companies are racing against 20-year patents while drugs take over 10 years to develop," explains Kozyra. "A lot of diseases cannot be cured because we cannot find the right molecule that will fix the protein. But the promise here is that you can actually cure potentially all diseases because all proteins come from mRNA." This inefficiency results in billions of dollars in costs and a 90% failure rate for new drugs, limiting patient access to life-saving innovations. **Nanorobots: The Future of Rapid Detection** Kozyra's solution lies in DNA nanorobots—self-assembling machines that can detect diseases in blood samples within 2-4 hours, a fraction of the time required by traditional methods. Unlike the metallic robots of science fiction, these biological machines are designed to produce fluorescent signals when they encounter specific DNA or RNA molecules, enabling rapid, accurate point-of-care diagnostics. "We are creating nanorobots that self-assemble into structures or dynamic devices," Kozyra states. "You simply add them to the sample, let them find the right markers, and they start producing a signal. If you can detect it, you know exactly what is in your sample." The technology has already proven its worth in a hospital study involving 170 patient samples. "In a clinical setting, our technology delivered the same or better results than traditional tests in just two hours instead of two days," Kozyra notes. "This is a gamechanger for emergency situations where immediate answers are critical." **Links **Disrupting Biotech: How DNA Nanorobots Are Rewriting the Rules of Drug Discovery, with Jurek Kozyra https://omny.fm/shows/disruption-interruption/disrupting-biotech-how-dna-nanorobots-are-rewriting-the-rules-of-drug-discovery-with-jurek-kozyra **LinkedIn:** https://www.linkedin.com/in/j3ny/ **Company Website:** https://nanovery.co.uk Disruption Interruption is the podcast where you will hear from today's biggest Industry Disruptors. Learn what motivated them to bring about innovation and how they overcame opposition to adoption. Disruption Interruption can be listened to in Apple's App Store and Spotify. **About Disruption Interruption™** Disruption is happening on an unprecedented scale, impacting all manner of industries— MedTech, Finance, IT, eCommerce, shipping, logistics, and more—and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, "THAT'S IT! I'VE HAD IT!"? Time to Disrupt and Interrupt with host Karla Jo "KJ" Helms, veteran communications disruptor. KJ interviews badasses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits—and not-so-common—that are changing our economic markets… and lives. Visit the world's key pioneers that persist to success, despite arrows in their backs at www.disruption-interruption.com. **About Jurek Kozyra** Jurek Kozyra is a pioneering deep-tech entrepreneur and researcher with over a decade of experience at the intersection of DNA nanotechnology, AI, and molecular nanomachines. As the founder and CEO of Nanovery, Jurek is leading the charge in transforming molecular medicine by developing bioanalytical platforms that accelerate the discovery and characterization of next-generation RNA therapeutics. With more than $7 million raised and partnerships with global pharmaceutical companies, Nanovery is on track to revolutionize how diseases are diagnosed and treated. Before founding Nanovery, Jurek honed up his expertise in academia, designing DNA-based nanodevices and pioneering algorithms that pushed the boundaries of computation and nanoscale biology. His multidisciplinary approach has enabled him to translate breakthrough science into commercial biotech solutions, bridging the gap between research and real-world applications. At Nanovery, Jurek's mission is to drive innovation in the bioanalysis of RNA drugs, from high-throughput assay development to advanced data analytics, enabling safer and more effective treatments for complex diseases. His work has garnered attention from leading academics, industry partners, and cross-functional teams, solidifying his reputation as a visionary in the biotech space. **About Karla Jo Helms** Karla Jo Helms is the Chief Evangelist and Anti-PR® Strategist for JOTO PR Disruptors™. Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line — and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill into the good graces of public opinion — Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception. **References** 1. Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., & Southall, N. (2023). Clinical development times for innovative drugs. Nature Reviews Drug Discovery, 21(11). doi.org/10.1038/d41573-021-00190-9 Media Inquiries: Karla Jo Helms JOTO PR™ 727-777-4629 SOURCE Disruption Interruption ### Related Stocks - [CURE.AU - Mirae Asset Global Investments Co., Ltd.](https://longbridge.com/en/quote/CURE.AU.md) - [CURE.US - Direxion Healthcare Bull 3X](https://longbridge.com/en/quote/CURE.US.md) - [NNOX.US - Nano-X Imaging](https://longbridge.com/en/quote/NNOX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 尽管增长预测乐观，NanoXplore（TSX:GRA）第二季度的亏损延续了关于其盈利能力的争论 | NanoXplore（多伦多证券交易所代码：GRA）报告了 2026 年第二季度的收入为 2760 万加元，净亏损为 380 万加元，这引发了人们对其盈利能力前景的担忧。尽管预计年均收益增长为 66.33%，但该公司在过去六个季度中持续亏损 | [Link](https://longbridge.com/en/news/275826271.md) | | Nano-X Imaging 将在欧洲首次现场展示 Nanox.ARC，并在 ECR 2026 上展示新的人工智能功能 \| NNOX 股票新闻 | Nanox Imaging Ltd. 将于 2026 年 3 月 4 日至 8 日在欧洲放射学大会（ECR）上首次在欧洲现场展示其 Nanox.ARC 数字断层合成系统。该公司将介绍用于早期疾病检测的新人工智能能力以及关于肺癌筛查的新临床数 | [Link](https://longbridge.com/en/news/276128373.md) | | 人形机器人狂奔 2026：谁为盛宴买单？ | 2026 年春晚展示了四家国产机器人企业的技术成果，标志着中国人形机器人行业的快速发展。宇树科技、松延动力、魔法原子和银河通用的机器人在节目中表现出色，吸引了亿万观众的目光。这场盛宴不仅是技术的展示，更是商业化的关键时刻，企业们希望将知名度 | [Link](https://longbridge.com/en/news/276190831.md) | | 宇树机器人春晚武术表演再炸场，王兴兴：高动态高协同集群控制技术全球首秀 | 宇树科技创始人王兴兴表示，今年机器人的头部激光雷达、灵巧手等硬件和软件做了很多升级，“去年一整年，我们公司包括全中国的机器人的技术提升非常快，像我们公司的话，目前可以做各种的功夫动作，而且在舞台上面我们挑战了很多极限动作，可能一般的人，甚至 | [Link](https://longbridge.com/en/news/276086555.md) | | 智元发布新一代全尺寸人形机器人远征 A3 | 智元机器人于 2 月 13 日发布了新一代全尺寸人形机器人远征 A3，专注于导览导购和文娱商演等人机互动场景。该机器人具备超拟人全身自由度，手臂负载可达 3kg，最高速度为 2m/s，配备灵巧手。其创新的电池嵌入式躯干设计和双电池系统使其在 | [Link](https://longbridge.com/en/news/275868234.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.